UCB: Bimzelx ready to enter the PsA and AxspA arenas
UCB has revealed additional date on the performance of bimekuzimab in Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (AxspA). It is clear that the drug will be a strong contender in both indications, and from our initial view, it will blow the competition out of the water when it comes to TNFa non-responders in PsA. In AxspA the results are on par with the top biologicals and the PhIIb OLE indicates improved performance over time. This reinforces our view that UCB will overcome the CRL letter issue, reiterate our Buy rating and our € 125 PT.UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.